Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
302 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015’, provides an overview of the Graft Versus Host Disease (GVHD)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Graft Versus Host Disease (GVHD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Graft Versus Host Disease (GVHD) Overview 10 Therapeutics Development 11 Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 11 Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 12 Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 13 Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 18 Graft Versus Host Disease (GVHD) - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Graft Versus Host Disease (GVHD) - Products under Development by Companies 23 Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 27 Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 28 AbGenomics International, Inc. 28 Adienne Pharma & Biotech 29 Alder Biopharmaceuticals Inc. 30 Alexion Pharmaceuticals, Inc. 31 Apceth GmbH & Co. KG 32 Athersys, Inc. 33 Bellicum Pharmaceuticals, Inc. 34 Biogen Idec Inc. 35 Dr. Falk Pharma GmbH 36 Enlivex Therapeutics Ltd 37 Escape Therapeutics, Inc. 38 F. Hoffmann-La Roche Ltd. 39 Generon (Shanghai) Corporation Ltd. 40 Idera Pharmaceuticals, Inc. 41 ImmuNext, Inc. 42 Immunomedics, Inc. 43 Jazz Pharmaceuticals plc 44 Kadmon Corporation, LLC 45 Kamada Ltd. 46 Kymab Limited 47 Lycera Corp. 48 Mesoblast Limited 49 Millennium Pharmaceuticals, Inc. 50 MSM Protein Technologies, Inc. 51 Neopharm Ltd. 52 NeoStem, Inc. 53 Novartis AG 54 Omni Bio Pharmaceutical Inc. 55 Pharmacyclics, Inc. 56 Pharmicell Co., Ltd. 57 Pluristem Therapeutics Inc. 58 R-Tech Ueno, Ltd. 59 REGiMMUNE Corporation 60 Rigel Pharmaceuticals, Inc. 61 Sarepta Therapeutics, Inc. 62 Seattle Genetics, Inc. 63 Sigmoid Pharma Limited 64 Soligenix, Inc. 65 Spherium Biomed S.L. 66 Targazyme, Inc. 67 Therapix Biosciences Ltd 68 Tobira Therapeutics, Inc. 69 Xenikos B.V. 70 Graft Versus Host Disease (GVHD) - Therapeutics Assessment 71 Assessment by Monotherapy Products 71 Assessment by Combination Products 72 Assessment by Target 73 Assessment by Mechanism of Action 76 Assessment by Route of Administration 79 Assessment by Molecule Type 81 Drug Profiles 83 AbGn-168H - Drug Profile 83 aldesleukin - Drug Profile 85 Alecmestencel-L - Drug Profile 87 Alpha-1 Antitrypsin - Drug Profile 88 alpha-1 proteinase inhibitor (human) - Drug Profile 89 ALXN-1007 - Drug Profile 91 anti-thymocyte globulin (rabbit) - Drug Profile 92 Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 94 Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 95 ApoCell - Drug Profile 96 beclomethasone dipropionate - Drug Profile 97 begelomab - Drug Profile 99 bortezomib - Drug Profile 100 BPX-501 - Drug Profile 105 brentuximab vedotin - Drug Profile 107 budesonide - Drug Profile 112 Bz-423 - Drug Profile 115 cannabidiol - Drug Profile 116 Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile 117 Cell Therapy for CNS, Respiratory, Immunology and Metabolic Disorders - Drug Profile 119 Cell Therapy for Graft Versus Host Disease - Drug Profile 120 Cell Therapy for Graft Versus Host Disease - Drug Profile 121 Cell Therapy for Graft Versus Host Disease - Drug Profile 122 Cell Therapy for Graft versus Host Disease - Drug Profile 123 Cell Therapy for Graft-Versus Host Disease - Drug Profile 124 Cell Therapy for GVHD - Drug Profile 125 cenicriviroc mesylate - Drug Profile 126 Cerecellgram for Graft Versus Host Disease - Drug Profile 128 clazakizumab - Drug Profile 129 Coversin - Drug Profile 131 cyclosporine IR + cyclosporine CR - Drug Profile 132 defibrotide - Drug Profile 133 Drugs for Acute and Chronic GVHD - Drug Profile 136 Drugs for Graft Versus Host Disease - Drug Profile 137 erismodegib - Drug Profile 138 F-652 - Drug Profile 141 Fc-Alpha-1 Antitrypsin - Drug Profile 142 FcAAT-2 - Drug Profile 143 FcAAT-3 - Drug Profile 144 Ha-7 - Drug Profile 145 ibrutinib - Drug Profile 146 ImmuneSafe - Drug Profile 152 ImmuStem - Drug Profile 153 IMO-8400 - Drug Profile 154 inolimomab - Drug Profile 156 IT-603 - Drug Profile 157 IT-901 - Drug Profile 158 KD-025 - Drug Profile 159 KY-1005 - Drug Profile 161 milatuzumab - Drug Profile 162 Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 164 MSM-707 - Drug Profile 166 MultiStem - Drug Profile 167 natalizumab - Drug Profile 170 Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 172 panobinostat - Drug Profile 173 PLX-RAD - Drug Profile 179 Protein to Activate TLR5 for Infectious Disease and GVHD - Drug Profile 182 Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders - Drug Profile 183 Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 184 remestemcel-L - Drug Profile 185 RGI-2001 - Drug Profile 188 RO-2959 - Drug Profile 190 Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders - Drug Profile 191 Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorder - Drug Profile 192 Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile 193 Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 194 SP-12008 - Drug Profile 195 T-Guard - Drug Profile 196 TZ-101 - Drug Profile 198 Graft Versus Host Disease (GVHD) - Recent Pipeline Updates 200 Graft Versus Host Disease (GVHD) - Dormant Projects 283 Graft Versus Host Disease (GVHD) - Discontinued Products 287 Graft Versus Host Disease (GVHD) - Product Development Milestones 288 Featured News & Press Releases 288 Appendix 296 Methodology 296 Coverage 296 Secondary Research 296 Primary Research 296 Expert Panel Validation 296 Contact Us 296 Disclaimer 297
List of Tables Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2015 16 Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H1 2015 17 Number of Products under Development by Companies, H1 2015 19 Number of Products under Development by Companies, H1 2015 (Contd..1) 20 Number of Products under Development by Companies, H1 2015 (Contd..2) 21 Number of Products under Development by Companies, H1 2015 (Contd..3) 22 Number of Products under Investigation by Universities/Institutes, H1 2015 23 Comparative Analysis by Late Stage Development, H1 2015 24 Comparative Analysis by Clinical Stage Development, H1 2015 25 Comparative Analysis by Early Stage Development, H1 2015 26 Comparative Analysis by Unknown Stage Development, H1 2015 27 Products under Development by Companies, H1 2015 28 Products under Development by Companies, H1 2015 (Contd..1) 29 Products under Development by Companies, H1 2015 (Contd..2) 30 Products under Development by Companies, H1 2015 (Contd..3) 31 Products under Investigation by Universities/Institutes, H1 2015 32 Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H1 2015 33 Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H1 2015 34 Graft Versus Host Disease (GVHD) - Pipeline by Alder Biopharmaceuticals Inc., H1 2015 35 Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 36 Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H1 2015 37 Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H1 2015 38 Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 39 Graft Versus Host Disease (GVHD) - Pipeline by Biogen Idec Inc., H1 2015 40 Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H1 2015 41 Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H1 2015 42 Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H1 2015 43 Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 44 Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 45 Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 46 Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H1 2015 47 Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H1 2015 48 Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals plc, H1 2015 49 Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H1 2015 50 Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H1 2015 51 Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H1 2015 52 Graft Versus Host Disease (GVHD) - Pipeline by Lycera Corp., H1 2015 53 Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H1 2015 54 Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 55 Graft Versus Host Disease (GVHD) - Pipeline by MSM Protein Technologies, Inc., H1 2015 56 Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H1 2015 57 Graft Versus Host Disease (GVHD) - Pipeline by NeoStem, Inc., H1 2015 58 Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H1 2015 59 Graft Versus Host Disease (GVHD) - Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 60 Graft Versus Host Disease (GVHD) - Pipeline by Pharmacyclics, Inc., H1 2015 61 Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H1 2015 62 Graft Versus Host Disease (GVHD) - Pipeline by Pluristem Therapeutics Inc., H1 2015 63 Graft Versus Host Disease (GVHD) - Pipeline by R-Tech Ueno, Ltd., H1 2015 64 Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H1 2015 65 Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 66 Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H1 2015 67 Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H1 2015 68 Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H1 2015 69 Graft Versus Host Disease (GVHD) - Pipeline by Soligenix, Inc., H1 2015 70 Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H1 2015 71 Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H1 2015 72 Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd, H1 2015 73 Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H1 2015 74 Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H1 2015 75 Assessment by Monotherapy Products, H1 2015 76 Assessment by Combination Products, H1 2015 77 Number of Products by Stage and Target, H1 2015 79 Number of Products by Stage and Mechanism of Action, H1 2015 82 Number of Products by Stage and Route of Administration, H1 2015 85 Number of Products by Stage and Molecule Type, H1 2015 87 Graft Versus Host Disease (GVHD) Therapeutics - Recent Pipeline Updates, H1 2015 205 Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2015 288 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H1 2015 289 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H1 2015 290 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H1 2015 291 Graft Versus Host Disease (GVHD) - Discontinued Products, H1 2015 292
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
